Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGOBONE regorafenib in metastatic bone sarcomas
2024-513455-33-00Phase 2Completed
- Sponsor
- Unicancer
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bone cancer, osteosarcoma (OS), Ewing sarcoma and 3 more comparing Regorafenib (Stivarga) with Placebo (2 arms). Primary endpoint: Non-progression rate at disease-specific timepoints. Started Sep 2014; status: completed.
02
Drugs
regorafenib
03
Conditions
bone cancerosteosarcoma (OS)Ewing sarcomachondrosarcomachordoma
Beyond the preview
Go deeper on 2024-513455-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513455-33-00.